Impact of Maternal Risk Stratification on Clinical Characteristics and Perinatal Outcomes in Singleton Pregnancies With Preeclampsia
The Journal of Clinical Hypertension · 2026-07 · 28 (7)
DOI: 10.1111/jch.70290 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Hypertension, online erschienen am 03.07.2026. Verfasst von Qian Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Department of Obstetrics and Gynecology, Fujian M…. Hauptthemen laut MEDLINE: Pre-Eclampsia. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Fujian Province of China, Fujian Provincial Health Technology Project, Startup Fund for scientific research, Fujian Medical University.
Abstract (Originalsprache)
This retrospective study of 4143 women at Fujian Maternal and Child Health Hospital (2012–2022) investigated how maternal risk levels influence clinical characteristics and perinatal outcomes in singleton pregnancies complicated by preeclampsia. Utilizing class‐imbalance‐adjusted and random forest algorithms, participants were stratified into high‐risk (17.38%), moderate‐risk (34.08%), and low‐risk (48.54%) groups. The analysis revealed that women in the high‐risk category were diagnosed at a significantly earlier gestational age and faced higher rates of severe, early‐onset, and preterm preeclampsia compared to the other groups. Although high‐risk pregnancies were associated with increased incidences of renal impairment, hypoproteinemia, and aminotransferase abnormalities, no significant differences were observed in rates of thrombocytopenia, placental abruption, postpartum hemorrhage, or stillbirth. Regarding delivery and neonatal outcomes, the high‐risk group demonstrated markedly higher rates of Cesarean sections, fetal distress, and neonatal intensive care unit (NICU) admissions. Key drivers of these adverse outcomes included chronic hypertension, chronic kidney disease, prior fetal growth restriction (FGR), and maternal age over 40 years. Ultimately, while high‐risk status is a strong predictor of early‐onset disease and specific maternal‐neonatal complications, it does not uniformly predict all adverse fetal outcomes, suggesting that clinical management should focus heavily on the specific impacts of hypertension, renal health, and advanced maternal age.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Department of Obstetrics and Gynecology, Fujian Maternity and Child Health Hospital.
- Fujian Maternity and Child Health Hospital, Fuzhou, Fujian, PR China.
ORCID-Profile: Jiaying Zheng
Förderung
- Natural Science Foundation of Fujian Province of China
- Fujian Provincial Health Technology Project
- Startup Fund for scientific research, Fujian Medical University
- Joint Funds for the Innovation of Science and Technology, Fujian province
Zitieren
APA
Yu, Q., Liang, Z., Zheng, J., Jin, C., Qi, X., Yan, J., & Xu, X. (2026). Impact of Maternal Risk Stratification on Clinical Characteristics and Perinatal Outcomes in Singleton Pregnancies With Preeclampsia. The Journal of Clinical Hypertension, 28(7). https://doi.org/10.1111/jch.70290
Vancouver
Yu Q, Liang Z, Zheng J, Jin C, Qi X, Yan J, et al. Impact of Maternal Risk Stratification on Clinical Characteristics and Perinatal Outcomes in Singleton Pregnancies With Preeclampsia. The Journal of Clinical Hypertension. 2026;28(7). doi:10.1111/jch.70290
BibTeX
@article{Yu2026,
author = {Yu, Qian and Liang, Zewei and Zheng, Jiaying and Jin, Chengcheng and Qi, Xingyi and Yan, Jianying and Xu, Xia},
title = {Impact of Maternal Risk Stratification on Clinical Characteristics and Perinatal Outcomes in Singleton Pregnancies With Preeclampsia},
journal = {The Journal of Clinical Hypertension},
year = {2026},
volume = {28},
number = {7},
doi = {10.1111/jch.70290}
}
EUVIMED